Knowledge and Perception Towards Psychotropic Drugs Among the General Population in Saudi Arabia.

Eatedal M Al-Shareef, Alaa M Kadah Salim, Nada M Al-Farrah, Bader M Al-Murad, Adnan A Moallem, Mohammed A Radwan, Salman Hakami, Asim M Alshanberi, Mohammed Shaikhomer, Safaa M Alsanosi
Author Information
  1. Eatedal M Al-Shareef: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  2. Alaa M Kadah Salim: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  3. Nada M Al-Farrah: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  4. Bader M Al-Murad: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  5. Adnan A Moallem: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  6. Mohammed A Radwan: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia. ORCID
  7. Salman Hakami: Department of Psychiatry, Mental Health Hospital, Ministry of Health, Jeddah, Saudi Arabia.
  8. Asim M Alshanberi: General Medicine Program, Batterjee Medical College, Jeddah, 21442, Saudi Arabia.
  9. Mohammed Shaikhomer: Department of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  10. Safaa M Alsanosi: Department of Pharmacology and Toxicology Faculty of Medicine, Umm Al Qura University, Makkah, Saudi Arabia. ORCID

Abstract

Background: Mental health is crucial to overall well-being. Despite an increase in mental disorders over the past few decades, public awareness remains slow-growing, and stigmatization towards psychotropic medications persists. Therefore, this study aimed to identify knowledge and perceptions of psychotropic drugs among the general population in the Makkah Region, Saudi Arabia.
Methods: A questionnaire-based cross-sectional study was conducted among adults aged 18 years old and older, living in the Makkah Region, Saudi Arabia, from 1 January to 30 April 2024. Descriptive statistics were used to describe participants' characteristics, and categorical variables were reported as frequencies and percentages. A Chi-square test was used to examine the relationships between variables.
Results: A total of 717 participants were involved in the study: (52%) were from Jeddah, (25.9%) were from Taif, and (22%) were from Makkah. The mean age was 33.9 years, and 67.1% were females. Among the participants, (20.8%) had experienced a psychiatric illness, (41.7%) had a member of the family who suffered from a psychiatric illness, (39.5%) had a family member who used a psychiatric drug, and only 25 (7%) had a child suffering from a psychiatric illness. Specifically, 20.8% of those with a psychiatric illness demonstrated good knowledge (P=0.001), 16.1% of those with a family history of psychiatric illness had good knowledge (P=0.007), 16.3% with family use of psychiatric drugs had good knowledge (P=0.006), and 24.5% of those who used psychiatric drugs had high knowledge (P=0.001). Overall, (40.6%) of participants had a low level of knowledge and perception about psychotropic drugs, (47.8%) had a moderate knowledge and perception level, and only (11.6%) had high knowledge and perception.
Conclusion: Psychological well-being is crucial for health, but misconceptions persist, acting as barriers that impede people from seeking and accepting necessary psychiatric care. The findings highlight the need for targeted public education and healthcare professional training to improve Confirmed understanding and reduce stigma around psychotropic drugs in Saudi Arabia. A multifaceted approach involving policy development, community outreach, and ongoing research is essential for enhancing mental health outcomes and treatment accessibility.

Keywords

References

  1. Cureus. 2022 Feb 6;14(2):e21965 [PMID: 35155046]
  2. Heliyon. 2022 Oct 18;8(10):e11084 [PMID: 36303905]
  3. Neurosciences (Riyadh). 2016 Jan;21(1):37-42 [PMID: 26818165]
  4. Sultan Qaboos Univ Med J. 2023 May;23(2):190-197 [PMID: 37377817]
  5. World Psychiatry. 2002 Feb;1(1):16-20 [PMID: 16946807]
  6. Health Soc Care Community. 2022 Nov;30(6):e5968-e5978 [PMID: 36148522]
  7. J Affect Disord. 2022 Apr 15;303:273-285 [PMID: 35176342]
  8. Cureus. 2023 May 26;15(5):e39549 [PMID: 37250612]
  9. BMC Psychiatry. 2018 Mar 13;18(1):66 [PMID: 29534695]
  10. Am J Orthopsychiatry. 2007 Oct;77(4):534-42 [PMID: 18194033]
  11. Int J Environ Res Public Health. 2021 Jan 06;18(2): [PMID: 33418993]
  12. Rev Paul Pediatr. 2022 May 11;40:e2021012 [PMID: 35584415]
  13. Psychiatr Serv. 2012 Oct;63(10):963-73 [PMID: 23032675]
  14. PLoS One. 2021 Jan 7;16(1):e0245156 [PMID: 33411793]
  15. J Family Community Med. 2008 Jan;15(1):35-42 [PMID: 23012165]
  16. Indian J Psychiatry. 2019 Sep-Oct;61(5):503-507 [PMID: 31579196]
  17. Front Public Health. 2021 Oct 06;9:747953 [PMID: 34692630]
  18. Medicine (Baltimore). 2020 Jan;99(1):e18635 [PMID: 31895824]
  19. Neurosciences (Riyadh). 2018 Jul;23(3):239-243 [PMID: 30008000]
  20. Ann Gen Psychiatry. 2023 Dec 14;22(1):54 [PMID: 38098047]
  21. Curr Psychiatry Rep. 2017 May;19(5):28 [PMID: 28425023]
  22. Syst Rev. 2020 Jan 16;9(1):17 [PMID: 31948489]
  23. Patient Prefer Adherence. 2016 Jul 22;10:1289-98 [PMID: 27524884]
  24. Patient Prefer Adherence. 2023 Nov 09;17:2877-2890 [PMID: 37965438]
  25. Healthcare (Basel). 2023 Dec 29;12(1): [PMID: 38200990]
  26. Int J Ment Health Syst. 2021 Oct 18;15(1):77 [PMID: 34663399]
  27. Scand J Public Health. 2022 Dec;50(8):1124-1132 [PMID: 34609273]
  28. Healthcare (Basel). 2023 May 14;11(10): [PMID: 37239709]
  29. Cureus. 2024 Feb 20;16(2):e54539 [PMID: 38516450]
  30. Int J Environ Res Public Health. 2022 Aug 04;19(15): [PMID: 35954954]
  31. Front Psychiatry. 2022 Jul 26;13:898009 [PMID: 35958637]

Word Cloud

Created with Highcharts 10.0.0knowledgepsychiatricdrugspsychotropicSaudiArabiaillnessusedfamilyP=0perceptionhealthMakkahparticipants8%goodcrucialwell-beingmentalpublicstudyamongRegionyearsvariables251%Among207%member5%00116high6%levelBackground:MentaloverallDespiteincreasedisorderspastdecadesawarenessremainsslow-growingstigmatizationtowardsmedicationspersistsThereforeaimedidentifyperceptionsgeneralpopulationMethods:questionnaire-basedcross-sectionalconductedadultsaged18oldolderliving1January30April2024Descriptivestatisticsdescribeparticipants'characteristicscategoricalreportedfrequenciespercentagesChi-squaretestexaminerelationshipsResults:total717involvedstudy:52%Jeddah9%Taif22%meanage33967femalesexperienced41suffered39drugchildsufferingSpecificallydemonstratedhistory0073%use00624Overall40low47moderate11Conclusion:PsychologicalmisconceptionspersistactingbarriersimpedepeopleseekingacceptingnecessarycarefindingshighlightneedtargetededucationhealthcareprofessionaltrainingimproveConfirmedunderstandingreducestigmaaroundmultifacetedapproachinvolvingpolicydevelopmentcommunityoutreachongoingresearchessentialenhancingoutcomestreatmentaccessibilityKnowledgePerceptionTowardsPsychotropicDrugsGeneralPopulation

Similar Articles

Cited By